We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+14.29%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$609M
AUM Growth
+$24.8M
Cap. Flow
-$43.5M
Cap. Flow %
-7.14%
Top 10 Hldgs %
99.31%
Holding
17
New
1
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ENTL
Entellus Medical, Inc. Common Stock
ENTL
+$9.16M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.3M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$11.6M
3
TTOO
T2 Biosystems, Inc
TTOO
+$4.89M

Sector Composition

Rank Sector Weight
1 Healthcare 79.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$386M 63.39%
4,188,920
– –
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$74.1M 12.18%
2,990,000
– –
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
$43.1M 7.08%
7,480,887
– –
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
$42M 6.89%
837,125
– –
ASXC
5
DELISTED
Asensus Surgical, Inc.
ASXC
$14.8M 2.43%
795,063
– –
ADMA icon
6
ADMA Biologics
ADMA
$2.03B
$11.1M 1.83%
3,608,171
– –
ENTL
7
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$9.76M 1.6%
+528,655
New +$9.16M
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$8.27M 1.36%
51,057
– –
AGRX
9
DELISTED
Agile Therapeutics
AGRX
$8.05M 1.32%
902
– –
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.49M 1.23%
50,857
– –
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
$2.48M 0.41%
472,943
– –
PTX
12
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$662K 0.11%
210,000
– –
TTOO
13
DELISTED
T2 Biosystems, Inc
TTOO
– –
-305
Closed -$4.89M
ARAV
14
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-337,411
Closed -$35.3M
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-482,680
Closed -$11.6M
ZLTQ
16
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$0 ﹤0.01%
11,985
– –

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Aisling Capital held 17 positions worth $609M, up 4.3% from $584M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital withdrew a net $43.5M in Q3 2017, closing 3 positions. Its most notable exit was Aravive, Inc. Common Stock, an estimated $35.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 79% a quarter earlier.

Against the trend, Aisling Capital opened a new position in Entellus Medical, Inc. Common Stock worth $9.76M.

  • Aisling Capital's largest Q3 2017 buy was Entellus Medical, Inc. Common Stock: 528,655 shares worth $9.76M.
  • Aisling Capital fully exited Aravive, Inc. Common Stock in Q3 2017, selling an estimated $35.3M.
  • Aisling Capital's ten largest holdings make up 99% of its $609M portfolio in Q3 2017.
  • Aisling Capital opened 1 new position and closed 3 in Q3 2017.
  • Aisling Capital's portfolio value rose 4.3% quarter-over-quarter to $609M.

Based on Aisling Capital's 13F filing for Q3 2017, filed 9 Nov 2017.